市场调查报告书
商品编码
1423209
2024-2032 年按类型(肌钙蛋白、心肌肌酸激酶、肌红蛋白、脑钠尿肽或NT-proBNP、缺血修饰白蛋白等)、测试地点、应用和区域分類的心臟生物标记市场报告Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2024-2032 |
2023年,全球心臟生物标记市场规模达到107亿美元。展望未来, IMARC Group预计到2032年市场规模将达到210亿美元,2024-2032年复合年增长率(CAGR)为7.6%。
心臟标记物,也称为心臟生物标记物,当心臟受到压力或肌肉受损时,会释放到血液中。这些标记物包括不同类型的酵素、荷尔蒙和蛋白质,例如心肌肌钙蛋白、肌酸激酶 (CK)、缺血修饰白蛋白 (IMA) 和肌红蛋白。测量和测试这些标记物可以帮助诊断心臟疾病,如心肌缺血和急性冠状动脉综合症 (ACS)。目前,用于确定这些病症风险的分类和诊断系统是基于心电图 (ECG) 和临床病史。然而,这些系统不足,可能导致误诊或延误治疗。由于心臟标记测试具有更高的准确性,并且可以在发病的早期阶段识别病情,因此它们在全球范围内获得了广泛的关注。这些标记还可以帮助更准确地监测这些疾病的预后,并为患者提供最有效的治疗。
在过去的几年中,患有 ACS 的患者数量不断增加,这在全球范围内产生了对心臟标记检测的需求。除此之外,患者和医疗保健提供者对各种心血管疾病早期诊断重要性的认识不断提高,推动了对这些标记物的需求。此外,还有许多私人和公共组织正在投资研发活动,以开发心臟生物标记领域的先进技术。例如,高敏感性心肌肌钙蛋白 I 的血液检测已被证明可以识别二次心臟病发作风险较高的患者。此外,生物标记测试提供的高精度和快速结果,再加上负担得起的心臟护理点测试的可用性,是促进市场成长的其他一些因素。
The global cardiac biomarkers market size reached US$ 10.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.6% during 2024-2032.
Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.
Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cardiac biomarkers market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on type, location of testing, and application.
Troponins (T and I)
Myocardial Muscle Creatine Kinase (CK-MB)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia Modified Albumin (IMA)
Others
Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.
Laboratory Testing
Point of Care Testing
Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.
North America
Asia Pacific
Europe
Middle East and Africa
Latin America
Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for majority of the global share.
The report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.